WO2009110010A3 - Forme posologique orale stable - Google Patents

Forme posologique orale stable Download PDF

Info

Publication number
WO2009110010A3
WO2009110010A3 PCT/IN2009/000163 IN2009000163W WO2009110010A3 WO 2009110010 A3 WO2009110010 A3 WO 2009110010A3 IN 2009000163 W IN2009000163 W IN 2009000163W WO 2009110010 A3 WO2009110010 A3 WO 2009110010A3
Authority
WO
WIPO (PCT)
Prior art keywords
olmesartan
amlodipine
dosage form
oral dosage
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000163
Other languages
English (en)
Other versions
WO2009110010A2 (fr
Inventor
Vaishali Vijay Dhavse
Nitin Bhalachandra Dharmadhikari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2009110010A2 publication Critical patent/WO2009110010A2/fr
Publication of WO2009110010A3 publication Critical patent/WO2009110010A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme posologique orale stable comportant des quantités thérapeutiquement efficaces d’amoldipine ou de son sel pharmaceutiquement acceptable et d’olmésartan ou de son sel pharmaceutiquement acceptable.
PCT/IN2009/000163 2008-03-07 2009-03-09 Forme posologique orale stable Ceased WO2009110010A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN478MU2008 2008-03-07
IN478/MUM/2008 2008-03-07

Publications (2)

Publication Number Publication Date
WO2009110010A2 WO2009110010A2 (fr) 2009-09-11
WO2009110010A3 true WO2009110010A3 (fr) 2010-01-07

Family

ID=41056433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000163 Ceased WO2009110010A2 (fr) 2008-03-07 2009-03-09 Forme posologique orale stable

Country Status (1)

Country Link
WO (1) WO2009110010A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425859A1 (fr) * 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations de l'olmesartane
WO2016155815A1 (fr) 2015-04-01 2016-10-06 Ceva Sante Animale Forme posologique orale solide d'amlodipine et usages vétérinaires correspondants
WO2017068532A1 (fr) * 2015-10-23 2017-04-27 Ftf Pharma Private Limited Solution orale de dérivés de dihydropyridine
CN119868296A (zh) * 2025-02-14 2025-04-25 宁波大红鹰药业股份有限公司 一种奥美沙坦酯氨氯地平片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique

Also Published As

Publication number Publication date
WO2009110010A2 (fr) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2010123919A3 (fr) Inhibiteurs pipéridiniques de la janus kinase 3
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
WO2009114118A3 (fr) Compositions pharmaceutiques orales de buprénorphine et procédé d’utilisation
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2009066326A3 (fr) Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2012051559A3 (fr) Compositions et méthodes de traitement de l'hypertension artérielle pulmonaire
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d'ivabradine
EP2657231A4 (fr) Azoles substitués, ingrédient actif antiviral, composition pharmaceutique et leur procédé de préparation et d'utilisation
WO2009144550A3 (fr) Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l’hospitalisation ou à la mort
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
AU2012280198A8 (en) Darunavir combination formulations
WO2011104652A3 (fr) Compositions vétérinaires
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires
MX341976B (es) Formulaciones de darunavir.
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2008083130A3 (fr) Compositions à base de carvédilol
WO2012075015A3 (fr) Compositions pharmaceutiques orales de métronidazole
WO2011135580A3 (fr) Compositions pharmaceutiques de sirolimus
WO2010012459A3 (fr) Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques
WO2009133455A3 (fr) Composition pharmaceutique de clopidogrel
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
WO2009011901A3 (fr) Procédés pour favoriser la veille

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718495

Country of ref document: EP

Kind code of ref document: A2